U.S. FDA today authorized Cognoa’s machine learning-based software to help diagnose autism spectrum disorder. The de novo authorization from FDA covers the use of the Cognoa ASD Diagnosis Aid with children 18 months through 5 years of age with potential ASD symptoms. Palo Alto, Calif.–based Cognoa has touted the software as a way to do away […]
Autism
Neuroimaging could be the key to early autism diagnoses
Functional connectivity magnetic resonance imaging (fcMRI) may be able to predict the chances of developing autism by the age of 2 in high-risk 6-month old infants, according to a new study in the Science Translational Medicine journal. Autism is characterized by challenges in social skills, repetitive behaviors, speech and nonverbal communication. People with autism also […]
Augmentative and alternative communication: A new generation of tools for autism
Anticipating autism through functional neuroimaging
Is 9-month-old Mila Goshgarian at risk for developing autism spectrum disorder (ASD)? Her 4-year-old twin brothers are both on the spectrum, so statistically her chances are at least 20 percent.
Rett syndrome sees glimmer of hope in Phase I trial
This post is the first in a two-part series on clinical trials in autism spectrum disorders. Read part 2.
Autism clinical trials are ripe for improvement
Crunching the autism equation in the DSM-5 era
By Alal Eran
Alal Eran, PhD, studies the molecular basis of autism at Boston Children’s Hospital and Harvard Medical School.
Can Therapeutic Systems’ Vayu Vest change the way autism is treated?
For the parents of autistic children, few treatment options exist other than powerful anti-psychotic medications or alternative therapies with little supporting clinical evidence. Brian Mullen is hoping to break this pattern with the Vayu Vest, a device that uses a treatment method called "deep pressure touch simulation," one of the most well-established alternative therapies. Mullen hopes that his device will become the first FDA-approved medical device to treat autism.
